Get the Stockscreener App
1.03
0.00%
0.00
Icecure Medical Ltd stock is traded at $1.03, with a volume of 284.85K.
It is up +0.00% in the last 24 hours and down -9.65% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$1.03
Open:
$1.02
24h Volume:
284.85K
Relative Volume:
0.96
Market Cap:
$68.58M
Revenue:
$3.67M
Net Income/Loss:
$-13.83M
P/E Ratio:
-3.6786
EPS:
-0.28
Net Cash Flow:
$-10.79M
1W Performance:
-11.97%
1M Performance:
-9.65%
6M Performance:
+57.71%
1Y Performance:
-11.97%
1-Day Range:
$1.01
$1.10
1-Week Range:
$1.00
$1.1986
52-Week Range:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.03 | 68.58M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure Receives High Level of Interest from Breast Surgeons at - GuruFocus
Breast Cancer Treatment Breakthrough: Surgeons Rally Behind IceCure's Freezing Technology as FDA Approval Nears - Stock Titan
IceCure Medical Ltd (NASDAQ:ICCM) Shares Acquired by Geode Capital Management LLC - Defense World
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America - Barchart.com
IceCure Medical reports on FDA meeting for ProSense Cryoablation - TipRanks
ICCM Advances ProSense Approval with FDA Interface | ICCM Stock News - GuruFocus
IceCure Announces Positive FDA Development: Understanding on Pat - GuruFocus
FDA Clears Path for Revolutionary Breast Cancer Treatment: ProSense Set to Transform Care for 46,000 Patients - Stock Titan
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - GuruFocus
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems - marketscreener.com
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - StreetInsider
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation | ICCM Stock News - GuruFocus
Clinical Trial Reveals Revolutionary Breast Cancer Treatment: ProSense Shows 94% Success, Zero Complications - Stock Titan
IceCure Medical (NASDAQ:ICCM) Shares Down 3.1% – Time to Sell? - Defense World
IceCure Medical Announces Special Shareholder Meeting for May 2025 - TipRanks
FY2027 EPS Estimates for IceCure Medical Reduced by Analyst - Defense World
IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright - Defense World
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Zacks Investment Research
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer - Targeted Oncology
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target By Investing.com - Investing.com India
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target - Investing.com
IceCure Medical Reports Growth and Awaits FDA Decision - TipRanks
IceCure Medical Ltd’s Earnings Call: Growth Amidst Challenges - TipRanks
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - PR Newswire
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses By Investing.com - Investing.com South Africa
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses - Investing.com
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - StreetInsider.com
Earnings Outlook For Icecure Medical - Benzinga
IceCure Medical aims to bring cold cancer treatment to Vietnam - Mugglehead Magazine
IceCure Medical (ICCM) Projected to Post Earnings on Thursday - Defense World
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - The Malaysian Reserve
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Res - GuruFocus
IceCure reports high efficacy in kidney tumor cryoablation study By Investing.com - Investing.com South Africa
IceCure reports high efficacy in kidney tumor cryoablation study - Investing.com India
IceCure Medical Earnings: Cryoablation Pioneer Reports 2024 Results March 27 - Stock Titan
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - The Malaysian Reserve
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies - Targeted Oncology
IceCure stock tumbles after update on ProSense (ICCM:NASDAQ) - Seeking Alpha
IceCure Medical Ltd. Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense®? Cryoablation in Early-Stage Breast Cancer - Marketscreener.com
IceCure Medical Expects FDA Decision on ProSense After Q1 -March 20, 2025 at 09:20 am EDT - Marketscreener.com
IceCure nears FDA decision on breast cancer treatment - Investing.com
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):